Lineage Cell Therapeutics (LCTX) Convertible Debt (2014 - 2017)

Lineage Cell Therapeutics' Convertible Debt history runs 4 years deep, the most recent figure standing at $1.9 million for Q4 2017.

• In Q4 2017, Convertible Debt rose 80.72% year-over-year to $1.9 million; the TTM figure through Dec 2017 stood at $1.9 million (up 80.72% YoY), while the FY2017 annual figure was $1.9 million, up 80.72% from the prior year.
• Convertible Debt for Q4 2017 stood at $1.9 million, up from $1.1 million in the prior quarter.
• The five-year high for Convertible Debt was $1.9 million in Q4 2017, with the low at $60000.0 in Q4 2014.
• The 4-year median for Convertible Debt is $617908.0 (2015), against an average of $741132.4.
• The sharpest annual moves came in 2015 and 2016: Convertible Debt soared 440.0% in 2015, then slipped 26.33% in 2016.
• Lineage Cell Therapeutics' Convertible Debt stood at $60000.0 in 2014, then jumped by 440.0% to $324000.0 in 2015, then jumped by 218.52% to $1.0 million in 2016, then surged by 80.72% to $1.9 million in 2017.
• Business Quant data shows LCTX's Convertible Debt at $1.9 million in Q4 2017, $1.1 million in Q1 2017, and $1.0 million in Q4 2016.